Division of Hematology & Hematologic Malignancies, Department of Internal Medicine, University of Utah, United States of America.
Department of Medicine, Intermountain Medical Center, Intermountain Health, United States of America; Division of General Internal Medicine, Department of Internal Medicine, University of Utah, United States of America.
Thromb Res. 2024 Sep;241:109097. doi: 10.1016/j.thromres.2024.109097. Epub 2024 Jul 23.
Many patients with impaired renal function have concurrent indications for anticoagulant therapy, including atrial fibrillation and venous thromboembolism. For mild chronic kidney disease, data from clinical trials and existing guidelines can be applied to clinical management. The benefits and harms of anticoagulation therapy in patients with more advanced renal impairment are nuanced, as both thrombotic and bleeding risk are increased. Until recently, data regarding anticoagulants in severe renal impairment were primarily observational, but emerging evidence includes a few small clinical trials and the emergence of novel agents hypothesized to have improved efficacy and safety in this population. In this review, we summarize existing data on anticoagulation in patients with chronic kidney disease. We suggest a framework for anticoagulation decision-making in the burgeoning worldwide population of patients with chronic kidney disease.
许多肾功能受损的患者同时存在抗凝治疗的适应证,包括心房颤动和静脉血栓栓塞症。对于轻度慢性肾脏病,临床试验和现有指南中的数据可用于临床管理。在肾功能更严重受损的患者中,抗凝治疗的获益和危害较为复杂,因为血栓形成和出血风险均增加。直到最近,关于严重肾功能损害患者使用抗凝剂的数据主要是观察性的,但新出现的证据包括一些小型临床试验,以及假设在该人群中具有更好疗效和安全性的新型药物的出现。在这篇综述中,我们总结了目前关于慢性肾脏病患者抗凝治疗的数据。我们提出了一个在慢性肾脏病患者这一日益庞大的全球人群中进行抗凝决策的框架。